Current Report Filing (8-k)
September 09 2020 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): September 9, 2020
PASSAGE BIO, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-39231
|
|
82-2729751
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Two Commerce Square
2001 Market Street, 28th Floor
Philadelphia, PA
|
19103
|
(Address of principal executive offices)
|
(Zip Code)
|
(267) 866-0311
(Registrant’s telephone number,
including area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 Par Value Per Share
|
PASG
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01
|
Regulation FD Disclosure.
|
On September 9,
2020, Passage Bio, Inc. (the “Company”) updated its corporate presentation with information about the
Company, which it intends to use as part of investor presentations. A copy of the corporate presentation is attached as Exhibit
99.1 to this Current Report on Form 8-K.
The information
furnished with this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities
Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PASSAGE BIO, INC.
|
|
|
|
Date: September 9, 2020
|
By:
|
/s/ Richard Morris
|
|
|
Richard Morris
|
|
|
Chief Financial Officer
|
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Oct 2023 to Oct 2024